Human platelet aggregation tests in vitro. Effects of dilazep.
The effect of 1,4-bis-[3(3,4,,5-trimethoxybenzoyl-oxy)-propyl]-perhydro-1,4-diazepine (dilazep, Cormelian), a coronaroactive drug, was studied by various tests of hemostasis in vitro on human plasma. The antiplatelet action of the drug was clearly demonstrated: it inhibited, in appropriate concentrations, ADP, adrenaline and collagen induced aggregation platelet factor 3 (PF3) availability and clot retraction induced by ADP-reptilase. Conversely, coagulation tests as well as the lysis time of diluted whole blood were unaffected by the drug.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D001381:Azepines / Q000494:pharmacology*; D001777:Blood Coagulation; D003018:Clot Retraction; D003094:Collagen / Q000037:antagonists & inhibitors; D004109:Dilazep / Q000494:pharmacology*; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects*
D001381:Azepines; D000244:Adenosine Diphosphate; D003094:Collagen; D004109:Dilazep; D004837:Epinephrine